國家衛生研究院 NHRI:Item 3990099045/6739
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 856851      線上人數 : 937
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/6739


    題名: Immunological evaluation and comparison of different EV71 vaccine candidates
    作者: Chou, AH;Liu, CC;Chang, JY;Lien, SP;Guo, MS;Tasi, HP;Hsiao, KN;Liu, SJ;Sia, C;Wu, SC;Lee, MS;Hsiao, CH;Wang, JR;Chow, YH;Chong, P
    貢獻者: Division of Vaccine Research and Development
    摘要: Enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) are major causative agents of hand, foot, and mouth diseases (HFMDs), and EV71 is now recognized as an emerging neurotropic virus in Asia. Effective medications and/or prophylactic vaccines against HFMD are not available. The current results from mouse immunogenicity studies using in-house standardized RD cell virus neutralization assays indicate that (1) VP1 peptide (residues 211–225) formulated with Freund’s adjuvant (CFA/IFA) elicited low virus neutralizing antibody response (1/32 titer); (2) recombinant virus-like particles produced from baculovirus formulated with CFA/IFA could elicit good virus neutralization titer (1/160); (3) individual recombinant EV71 antigens (VP1, VP2, and VP3) formulated with CFA/IFA, only VP1 elicited antibody response with 1/128 virus neutralization titer; and (4) the formalin-inactivated EV71 formulated in alum elicited antibodies that cross-neutralized different EV71 genotypes (1/640), but failed to neutralize CVA16. In contrast, rabbits antisera could cross-neutralize strongly against different genotypes of EV71 but weakly against CVA16, with average titers 1/6400 and 1/32, respectively. The VP1 amino acid sequence dissimilarity between CVA16 and EV71 could partially explain why mouse antibodies failed to cross-neutralize CVA16. Therefore, the best formulation for producing cost-effective HFMD vaccine is a combination of formalin-inactivated EV71 and CAV16 virions.
    日期: 2012-09
    關聯: Clinical and Developmental Immunology. 2012 Sep;2012:Article ID 831282.
    Link to: http://dx.doi.org/10.1155/2012/831282
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000309012400001
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84867388819
    顯示於類別:[莊再成] 期刊論文
    [謝鐸源(2006-2014)] 期刊論文
    [周彥宏] 期刊論文
    [劉士任] 期刊論文
    [劉家齊] 期刊論文
    [李敏西] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PB2012102510.pdf567KbAdobe PDF690檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋